689
+3.45%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CanBas Co
Its shares trade on Tokyo Stock Exchange under the ticker 4575.T. It has been listed since 17 September 2009. In the fiscal year to 30 June 2022, it reported revenue of ¥53.5m and a net loss of ¥855.6m. At that date it held total assets of ¥790.7m and shareholders' equity of ¥250.7m.
CanBas Co., Ltd. engages in pharmaceutical business. The company is headquartered in Numazu-Shi, Shizuoka-Ken. The company went IPO on 2009-09-17. The firm is mainly engaged in the basic anticancer drug discovery research (including development of drug discovery concepts, selection of drug candidate compounds using methods based on these concept developments, simple animal studies, and collection and analysis of basic data on anticancer drug candidates that have entered development) and early clinical development (including preclinical studies prior to submission of applications to start clinical trials and the first part of clinical trials).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Sept 2009
- Employees
- 12
- Website
- canbas.co.jp ↗
Leadership
Pay as last reported
- Mr. Takumi KawabePresident, Representative Director, since 2001
- Mr. Makoto KatozumiChief Financial Officer, Manager of Business Planning Office, Director, since 2009
- Mr. Toshiyuki HibinoChief Operating Officer, Director of Research Development, Director, since 2020
- Mr. Kazuyoshi SakamotoDirector of Administration, Director, since 2010
- Mr. Toshio FurutaIndependent Director
- Mr. Yasuyuki KomiyamaIndependent Director
- Mr. Akio ShirakawaIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CanBas Co Ltd focuses on anticancer drug discovery with 12 employees in Numazu-shi, Japan.
- The company's early clinical development includes preclinical studies and first-phase trials.
- CanBas has a strong focus on basic anticancer drug research and development since 2009.
Weaknesses
- With only 12 employees, CanBas faces limited workforce capacity for expansion.
- The company's small size may hinder access to larger research funding opportunities.
- Limited employee count restricts the scope of their pharmaceutical research projects.
Opportunities
- Expanding anticancer drug research in Japan's growing Health Care sector.
- Collaborating with larger firms in the Biotechnology industry for resource sharing.
- Capitalizing on Japan's increasing focus on cancer treatment innovations.
Threats
- Competition from larger pharmaceutical companies in the Health Care sector.
- Regulatory challenges in the Biotechnology industry for new drug approvals.
- Economic downturns affecting investment in early-stage pharmaceutical research.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.